If you've just had a serious heart event like a heart attack, your biggest fear is probably having another one. Doctors call this cluster of events 'acute coronary syndrome.' After the initial scare, the focus shifts to preventing the next one—a heart attack, a stroke, or worse. A major study involving over 14,000 people recently wrapped up, testing a potential new layer of defense. The study looked at a drug called milvexian. Researchers wanted to know if adding milvexian to the standard medications and care people already receive would work better than that standard care plus a placebo (a dummy pill). The main thing they were watching for was whether milvexian could reduce the combined risk of three major problems: death from heart or blood vessel causes, a heart attack, or an ischemic stroke (a stroke caused by a blocked blood vessel in the brain). They tracked people for the time it took for the first of these events to happen. The study was designed to see if milvexian was superior, or better, at lowering this risk. The results of this large trial will help determine if this drug could become a new option for protecting hearts after a major scare.
Can a new drug help prevent heart attacks and strokes after a serious heart event?
Plain Language Summary
What this means for you:
A large trial tested if milvexian could better prevent major heart problems after a serious cardiac event. What this means for you:
A large trial tested if milvexian could better prevent major heart problems after a serious cardiac event. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE3
Condition(s): Acute Coronary Syndrome
Intervention(s): Milvexian (DRUG), Placebo (OTHER)
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Primary Outcome(s): Time to First Occurrence of Major Adverse Cardiovascular Event (MACE)
Enrollment: 14194 (ACTUAL)
Lead Sponsor: Janssen Research & Development, LLC
Start: 2023-04-07 | Primary Completion: 2026-02-06